3 Top Picks on Wall Street That Still Face Unresolved Issues

Wall Street’s Optimism and Overlooked Risks

Many analysts on Wall Street are highly optimistic about the stocks discussed below, with their price targets indicating the potential for notable gains. However, it's important to keep in mind that sell recommendations are rare, partly because analysts’ firms often have business relationships with the companies they evaluate.

At StockStory, our only priority is to help you discover truly promising investment opportunities, free from conflicts of interest. With that perspective, we’ve identified three stocks where Wall Street may be missing key risks, along with some alternatives that offer stronger fundamentals.

Zoom (ZM)

Analyst Price Target: $97.33 (suggesting a 29.7% potential increase)

Zoom (NASDAQ:ZM) became synonymous with remote work during the pandemic, offering a cloud-based suite for video conferencing, phone calls, messaging, and collaboration—connecting businesses and individuals worldwide.

Reasons to Be Cautious About ZM

• Billing growth averaged just 4% over the past year, indicating weak demand and the possibility that Zoom may need to cut prices to attract customers.
• Intense competition makes customer retention challenging, as reflected by a modest 98% net revenue retention rate.
• Sales are projected to grow only 4.2% over the next year, pointing to sluggish market interest.

Currently trading at $75.05, Zoom’s forward price-to-sales ratio stands at 4.6x.

JELD-WEN (JELD)

Analyst Price Target: $2.63 (implying a 73.8% upside)

JELD-WEN (NYSE:JELD), established in the 1960s, is a manufacturer of doors, windows, and related building products.

Why JELD May Not Be a Wise Investment

• For the past two years, the company has failed to achieve organic revenue growth, suggesting it may need to rely on acquisitions for expansion.
• Declining returns on capital from an already weak base indicate that past and current investments are not delivering expected benefits.
• A limited cash reserve raises the risk of a future capital raise, which could dilute existing shareholders’ stakes.

JELD-WEN shares are priced at $1.51, with a forward EV-to-EBITDA multiple of 9.5x.

Solventum (SOLV)

Analyst Price Target: $90.17 (projecting a 33.6% gain)

Solventum (NYSE:SOLV), founded in 1985, develops and markets a range of healthcare products and services designed to meet critical needs for both customers and patients.

Potential Concerns with SOLV

• Organic revenue growth has lagged expectations over the last two years, indicating a need to enhance product offerings, pricing, or sales strategies.
• Profitability has declined, with earnings per share dropping by an average of 31.6% annually over the past three years.
• Its free cash flow margin has decreased by 26.7 percentage points over four years, reflecting increased investments to maintain its market position.

Solventum is currently valued at $67.50 per share, trading at a forward P/E ratio of 10.4x.

Stocks With Stronger Potential

Don’t Miss Out: This Week’s Top 6 Stock Picks
The current market is quickly distinguishing high-quality stocks from overpriced ones, with AI-driven shifts impacting entire sectors unexpectedly. In such a fast-moving environment, a simple list of good companies isn’t enough.

Our AI-powered system identified Palantir before its 1,662% surge, AppLovin ahead of its 753% rally, and Nvidia prior to its 1,178% climb. Every week, it highlights six new stocks that meet the same rigorous criteria.

Past selections include well-known names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Kadant, which delivered a 351% five-year return.